Please ensure Javascript is enabled for purposes of website accessibility

Why TG Therapeutics Is Crashing Today

By James Brumley – Nov 15, 2021 at 3:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new call from a well-known Wall Street firms casts a fresh shadow of doubt on the drugmaker's actual revenue prospects.

What happened

Shares of biotechnology company TG Therapeutics (TGTX -3.40%) are down 15.3% in Monday's late trading following a downgrade from investment bank Goldman Sachs.

So what

TG Therapeutics' drug pipeline may not be as marketable as many investors believe it will be, according to Goldman Sachs analyst Corinne Jenkins. She downgraded the stock to a sell on Monday, citing limited revenue potential of its planned portfolio that's mostly being built around a single drug called umbralisib.

Businessman watching a falling chart lower itself out of sight,

Image source: Getty Images.

While the kinase inhibitor has already been proven and approved as a treatment for certain forms of lymphoma, and is showing promise as a therapy for multiple sclerosis, Jenkins argues that umbralisib's underlying mechanism of action is apt to be effective for a narrower range of indications than the company suggests and investors expect.

Now what

Some investors may be eyeing the stock as a prospective purchase due to the sheer scope of this year's sell-off. Shares were already down more than 40% from February's peak before today; Monday's steep plunge drives that loss to more than 50%. Such setbacks are relatively rare, and are often unwound without any real warning.

That's a bet, however, that wouldn't be wise to make in this particular situation.

Goldman's Jenkins may well be right -- the potential of TG Therapeutics' flagship research and development may be overestimated. The thing is, it doesn't entirely matter. The company remains deep in the red in the meantime, and in that it may also be years before its pipeline and portfolio are driving their peak revenue, it will likely remain in the red for the foreseeable future. None of this supports a bullish argument for the stock, but instead leaves it vulnerable to more of the same bearish rhetoric that's been driving it lower since early this year.

James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends TG Therapeutics. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.